NCT07088159AVAILABLEanonymous

Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor

Source record

Spinogenix

Phase

Source record

Expanded Access Program

Modality

AI-normalized

small molecule

Target

AI-normalized

Tazbentetol is hypothesized to modulate neural connectivity and synaptic function, potentially offering neuroprotective effects in ALS patients.

Indication / condition

AI-normalized

ALS (Amyotrophic Lateral Sclerosis)

Intervention

Source record

Tazbentetol

Source & freshness

Source record

NCT ID

NCT07088159

Original source

ClinicalTrials.gov

Source last updated

May 28, 2026

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07088159

Title

Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor

Spinogenix

Status

AVAILABLE

Phase

Expanded Access Program

Condition raw

ALS (Amyotrophic Lateral Sclerosis)

Condition normalized

ALS (Amyotrophic Lateral Sclerosis)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Tazbentetol is hypothesized to modulate neural connectivity and synaptic function, potentially offering neuroprotective effects in ALS patients.

Target normalized

Tazbentetol is hypothesized to modulate neural connectivity and synaptic function, potentially offering neuroprotective effects in ALS patients.

Interventions

Tazbentetol

Public preview

Source record

Spinogenix is advancing tazbentetol through an Expanded Access Program aimed at ALS patients who are ineligible for clinical trials. This initiative not only addresses an unmet medical need but also positions Spinogenix favorably within the ALS treatment landscape, which is characterized by limited therapeutic options. The program may enhance brand visibility and patient engagement, potentially leading to future market opportunities. Given the increasing prevalence of ALS and the demand for innovative therapies, successful outcomes could attract interest from investors and collaborators, while also providing valuable real-world evidence to support regulatory submissions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT07088159

Status

AVAILABLE

Phase

Expanded Access Program

Sponsor

Spinogenix

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 28, 2026

Internal syncJun 13, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07088159

Indication

ALS (Amyotrophic Lateral Sclerosis)

Modality

small molecule

Target

Tazbentetol is hypothesized to modulate neural connectivity and synaptic function, potentially offering neuroprotective effects in ALS patients.

Intervention

Tazbentetol

Source record